



MASTER

*In decision making
with*



Dr. S. H. Advani
Program Director

EMPOWER 2026

 **18th & 19th APRIL 2026**

 **Hotel Taj Santacruz, Mumbai**

PlanMyTreatment
Your home for better treatment

 **Helping Hand**
Cancer Care

 **ACADEMY OF CANCER CARE
FOUNDATION AND
RESEARCH CENTER**

Scan & Register



You, Myself & Everybody

Face problems in our life in different ways,
but what's more important is no matter what the problem is
we have to GET UP & KEEP MOVING forward



- Padmashree Dr. Suresh H. Advani

Dr. Suresh H. Advani, a renowned oncologist with prestigious fellowships, leads as Chief of Medical Oncology in multiple top hospitals, demonstrating excellence in cancer care. His inspirational journey from overcoming polio to receiving the Padma Bhushan inspires dedication to cancer treatment and medical education. Participating in global programs like ICRET, he shapes expertise in bone marrow transplantation and oncology.

As an educational advocate, he breaks barriers and mentors future medical professionals, fostering inclusivity in the field. Dr. Advani's pioneering work includes conducting India's first successful bone marrow transplant, establishing vital cancer treatment infrastructure. With over 50 years of experience, his

clinical excellence and research advancements contribute significantly to cancer treatment. Known for his patient-centric approach, he provides holistic support alongside medical treatment, instilling hope and compassion.

Internationally recognized, his contributions elevate cancer care standards globally, leaving a lasting leadership legacy as Chief of Tata Memorial Hospital's Cancer Department, inspiring future generations of oncologists. Treatment facility available under Ayushman Bharat scheme Treatment facility available under MVSSY scheme (Mukhyamantri Vishesh Swasthya Sahayata Yojana)

Confirmed Doctors

Dr. Adwaita Gore
Dr. A P Dubey
Dr. A.K.Ganju
Dr. Amit Joshi
Dr. Anbarasan Sekar
Dr. Anil Heroor
Dr. Anjana Sainani
Dr. Ankit Patel
Dr. Anshul Agarwal
Dr. Balkrishna Padate
Dr. Bharat Bhosale
Dr. Bharat Patodiya
Dr. Bhuvan Chugh
Dr. Boman Dhabhar
Dr. Chetan Damne
Dr. Chetan Deshmukh
Dr. Chintan Vyas
Dr. Darshana Rane
Dr. Darshit Shah
Dr. Deba Dulal Biswal
Dr. Dinesh Pendarkar
Dr. Ganesh Nagarajan
Dr. Ganpati Bhat
Dr. Gaurav Narula
Dr. Gayatri Raheja
Dr. Govind Babu
Dr. Hamza Dalal
Dr. Imran Sheikh
Dr. Harshit Shah
Dr. Hemant Malhotra
Dr. Indoo Ammbulkar
Dr. Jeyhan Dhabhar
Dr. Jimmy Dadhania
Dr. Jyoti Bajpai

Dr. Kalpana Velaskar
Dr. Karuna Luthra
Dr. Kaushal Patel
Dr. Kiran Tamkhane
Dr. Kirti Sabnish
Dr. Kripa Bajaj
Dr. Kritika Mehrotra
Dr. Madhura Agre
Dr. Mangesh Patil
Dr. Mohit Sharma
Dr. Mubarakunnisa Tonse
Dr. Mukesh Desai
Dr. Neha Patel
Dr. Nilesh Dhamane
Dr. Nilesh Mahale
Dr. Niti Raizada
Dr. P N Jain
Dr. Parth Ganatra
Dr. Pranav Chaddha
Dr. Prasad Dandekar
Dr. Prashant Nyati
Dr. Pratik Chandrakant Doshi
Dr. Pritam Kataria
Dr. P S R K Sastry
Dr. Rajas Patel
Dr. Ramakant Deshpandey
Dr. Reetu Jain
Dr. Ritika Bhandari
Dr. Rohit Malde
Dr. Rup Jyoti Sarma
Dr. Sameer Tulpule
Dr. Sandeep Bipte
Dr. Sandeep Batra
Dr. Sangeeta Jiwatani

Dr. Sanjay Agarwal
Dr. Santanu Sen
Dr. Satish Rao
Dr. Sobin George
Dr. Soumil Vyas
Dr. Sewanti Limaye
Dr. Shabaaz Khan
Dr. Shailesh Bondarde
Dr. Shalaka Joshi
Dr. Shirish Alurkar
Dr. Shishir Shetty
Dr. Shivam Shingla
Dr. Shrinath Kshirsagar
Dr. Srinivas Raut
Dr. Subhash Ranjan
Dr. Suhas Aagre
Dr. Suman Mittal
Dr. Sumant Gupta
Dr. Sunil Chopade
Dr. Sunit Lokwani
Dr. Suvarna Achrekar
Dr. Sweta Bansal
Dr. Tapan Saikia
Dr. Tejinder Singh
Dr. Trinanjan Basu
Dr. Trupti Pai
Dr. Udip Maheshwari
Dr. Varun Bafna
Dr. Varun Nagori
Dr. Viraj Borgaonkar
Dr. Vijay Patil
Dr. Vijay Sharnangat

HALLA

SESSION 1

08:50 - 09:00 ➤ Head & Neck Cancer Introduction & Opening by **Dr. Suresh Advani**

CHAIRPERSON : Dr. Anil D'Cruz | Dr. Satish Kamath | Dr. Sanjay Dudhat

09:00 - 09:20 ➤ “In a Resectable Locally Advanced Head & Neck Cancer Patient, Should We Prefer Next-Gen Precision Surgery Over Conventional Surgery?”

TEAM A : Precision Surgery Approach (AI + Fluorescence + Function preservation)

DEBATE : Expert of the field

TEAM B : Standard Surgical Approach

DEBATE : Expert of the field

DISCUSSANT : Expert of the field

09:20 - 09:40 ➤ Perioperative Immunotherapy in H & N Cancer The Pit Falls and The Gains

SPEAKER : Expert of the field

09:40 - 10:00 ➤ De-escalation Strategies in HPV-positive Oropharyngeal Cancer ' adoptive ratio therapy and role of AI in RT

SPEAKER : Dr. Kaustav Talpatra

10:00 - 10:20 ➤ Optimising Immunotherapy sequencing in H & N, peri Operative VS Adjuvent In High Risk HNSCC Cancers

SPEAKER : Dr. Suresh Advani

10:20 – 10:45 ➤ Recurrent & Metastatic Head & Neck Cancer:
Evolving Treatment Paradigm Points to cover - Cost effective care in real world

MODERATOR : Dr. Adwaita Gore

PANELIST : Dr. Burhanuddin N Qayyumi

Dr. Darshana Rane		Dr. Darshit Shah		Dr. Imran Shaikh
Dr. Kritika Mehrotra		Dr. Satish Rao		Dr. Shishir Shetty
Dr. Devendra Chaukar		Dr. A P Dubey		Dr. Trinanjan Basu
Dr Ajinkya Gupte				

10:45 - 11:00 ➤ **WORKING TEA BREAK**

SESSION 2

CHAIRPERSON : Dr. B K Smruti

- 10:45 - 11:00 ➤ Axillary Management After Neoadjuvant Therapy in cN1 Breast Cancer: Can We Safely Omit ALND?
SPEAKER : Dr. Sandeep Bipte
- 11:00 - 11:20 ➤ Chemotherapy in Early Breast Cancer: Still Essential or Selectively Avoidable?
TEAM A : Chemotherapy is STILL ESSENTIAL
DEBATE : Expert of the field
TEAM B : Chemotherapy is SELECTIVELY AVOIDABLE
DEBATE : Expert of the field
DISCUSSANT : Expert of the field
- 11:20 - 11:40 ➤ HR+ HER2? Early Breast Cancer: How Far Should We Escalate Adjuvant Therapy (CDK4/6 inhibitors for All or Selected)? Sponsored Talk **SPEAKER : Expert of the field**
- 11:40 - 12:00 ➤ Early TNBC in 2026: Is Checkpoint Inhibitor-Based Neoadjuvant Therapy the New Standard for Every Stage II-III Case? Sponsored Talk **SPEAKER : Expert of the field**
- 12:00 - 12:25 ➤ Panel Discussion: Revolutionising Adjuvant Therapy **SPEAKER : Expert of the field**
- 12:25 - 12:45 ➤ ctDNA and MRD in HR+ Breast Cancer: Should a Positive Assay Trigger Therapy Change Outside Clinical Trials? **SPEAKER : Dr. Anita Ramesh**
- 12:45 - 13:05 ➤ HER2-Low and Ultra-Low Disease: Re-writing Algorithms for "HER2-Negative" mBC in the Era of ADCs **SPEAKER : Expert of the field**
- 13:05 - 13:30 ➤ Panel Discussion - Maintenance After Induction: Tucatinib or Palbociclib Additions?
MODERATOR : Dr. Jyoti Bajpai
PANELIST :
- | | | |
|---------------------|----------------------|---------------------|
| Dr. Ankit Patel | Dr. Gayatri Raheja | Dr. Trupti Pai |
| Dr. Madhura Aagre | Dr. Suvarna Achrekar | Dr. Suman Mittal |
| Dr. Aditi Agrawal | Dr. Merlyn Matchvel | Dr. Toshita Jain |
| Dr. Aditya Punamiya | Dr. Rohit Malde | Dr. Ritika Bhandari |
- 13:30 - 14:00 ➤ **LUNCH BREAK**

SESSION 3

CHAIRPERSON : Dr. B K Smruti

14:00 - 14:20 ➤ Tissue vs Time: Should Comprehensive Molecular Diagnosis Delay Treatment in Lung Cancer?

TEAM A : Tissue First: Wait for Complete Molecular Diagnosis

DEBATE : Expert of the field

TEAM B : Time First: Start Treatment Without Delay

DEBATE : Expert of the field

DISCUSSANT : Expert of the field

14:20 - 14:40 ➤ The Emerging Role of Antibody Drug Conjugates in Lung Cancer

SPEAKER : Expert of the field

14:40 - 15:00 ➤ Treatment Evolution of Non Squamous Non-small Cell Lung Cancer

SPEAKER : Expert of the field

15:00 - 15:20 ➤ Serplulimab in Lung Cancer :
Setting New Benchmarks in Survival

SPEAKER : Expert of the field

15:20 - 15:40 ➤ Conquering ALK+ Lung Cancer Frontiers

SPEAKER : Expert of the field

15:40 - 16:00 ➤ A tale of 2 stories : Redefining Treatment Outcomes
with MARIPOSA-2 and PAPILLON

SPEAKER : Expert of the field

16:00 - 16:25 ➤ Panel Discussion - Boarder Line Recetable NSCLC - The Best Approach?

MODERATOR : Dr. Chetan Deshmukh

PANELIST :	Dr. Niti Raizada		Dr. Anjana Sainani		Dr. Anshul Agarwal
	Dr. Avinash Deo		Dr. Deba Dulal Biswal		Dr. Jeyhan Dhabhar
	Dr. Suhas Aagre		Dr. Shivam Shingla		Dr. Varun Nagori
	Dr. Prateek Patil		Dr. Ashish Gupta		

SESSION 4

- 16:25 ➤ **WORKING TEA BREAK**
- 16:25 - 16:55 ➤ **CHAIRPERSON : Dr. Prashant Kerkar | Dr. Shyam Agrawal**
 ➤ Upfront Surgery vs Perioperative Chemotherapy in Gastric Cancer: Standard or Shift?
TEAM A - Upfront Surgery by GI Surgeon
DEBATE : Expert of the field
TEAM B - Perioperative Chemotherapy by Medical Oncology
DEBATE : Expert of the field
DISCUSSANT : Expert of the field
- 16:55 - 17:15 ➤ Rationale to practice- Role of Tislelizumab in lung & esophageal carcinoma (Glenmark) **SPEAKER : Dr. Indoo Ammbulkar**
- 17:15 - 17:35 ➤ Redefining first-line HCC therapy with CheckMate-9DW -Sponsored Panel Discussion **SPEAKER : Expert of the field**
- 17:35 - 17:55 ➤ Evolving Paradigms in Gastric Cancer: From Evidence to Clinical Practice **SPEAKER : Expert of the field**
- 17:55 - 18:15 ➤ Illuminating CLDN18.2: Understanding novel biomarkers and Treatment Evolution with VYLOY **SPEAKER : Expert of the field**
- 18:15 - 18:35 ➤ A New Era in Managing Resectable Gastric Cancer with D+FLOT...!!! **SPEAKER : Expert of the field**
- 18:35 - 19:00 ➤ Surgical Perspectives in Hepatobiliary Malignancies: Multidisciplinary Management of Pancreas, Gall Bladder & Cholangiocarcinoma
MODERATOR : Dr. Soumil Vyas
PANELIST : Dr. Kaushal Patel | Dr. Rajas Patel | Dr. Nilesh Dhamane
 Dr. Sanjay Agarwal | Dr. Viraj Borgaonkar | Dr. Vijay Sharnangat
 Dr. Pranav Chadha | Dr. Karuna Luthra | Dr. Neha Patel
 Dr. Nilesh Mahale | Dr. Tejinder Singh | Dr. Harshit Shah
 Dr. Mubarakunnisa Tonse | Dr. Kiran Tamkhane
- 19:00 – 19:20 ➤ Keynote Speaker - Biliary Tract Cancers: Molecular Profiling & Systemic Advances - Focus on IDH1 Blockade **SPEAKER : Expert of the field**
- 19:20 – 19:45 ➤ Panel Discussion - Improving OS and QoL: Maximising Patient Outcomes in Unresectable Hepatocellular Carcinoma
SPEAKER : Expert of the field
- 19:45 – 20:30 ➤ Planetary Session

SESSION 5

CHAIRPERSON : Dr. Shirish Alurkar | Dr. Dinesh Pendharkar

09:00 - 09:20 ➤ Radical Prostatectomy vs Radiotherapy in Localized Prostate Cancer:
Which Offers Better Outcomes?

TOPIC 1 - Radical Prostatectomy by Uro Onco Surgeon

DEBATE : Expert of the field

TOPIC 2 - Radiotherapy ± ADT by Radiation Oncologist

DEBATE : Expert of the field

09:20 - 09:40 ➤ Checkpoint Revolution in Bladder Cancer: Expanding IO Horizon

SPEAKER : Expert of the field

09:40 - 10:00 ➤ Enfortumab Vedotin Relapsed/ Refractory
Bladder Cancer + Panel Discussion

SPEAKER : Expert of the field

10:00 - 10:20 ➤ “ctDNA in GU Cancers: Ready for Prime Time?”

SPEAKER : Dr. Sandeep Batra

10:20 - 10:40 ➤ GU Cancers in the Modern Era: Surgery, Systemic Therapy or Radiation –
Who Leads the Strategy?

MODERATOR : Dr. Amit Joshi

PANELIST :

Dr. Rahul Pathade		Dr. Indoo Ambulkar
Dr. Jimmy Dadhania		Dr. Pritam Kataria
Dr. Tejinder Singh		Dr. Sunil Chopade
Dr. Rup Jyoti Sharma		Dr. Pushpak Chirmade
Dr. Shivam Shingla		Dr. Shirish Alurkar
Dr. Anbarasan Sekar		

10:40 - 11:05 ➤ Darolutamide in Arano: A New Benchmark in mHSPC Therapy

SPEAKER : Expert of the field

11:05 - 11:20 ➤ **TEA BREAK**

SESSION 6

CHAIRPERSON : Dr. Shubhash Ranjan | Dr. Maheboob Basade

11:20 - 11:40 ➤ Management of stage 1 CA Endometrium Role of Bio Marker Driven Strategy

SPEAKER : Dr. B K Smruti

11:40 - 12:00 ➤ Is Aggressive Surgery Still the Cornerstone in the Era of Targeted Therapy?

TEAM A - Maximal Cytoreductive Surgery (Tumor Burden Reduction)

DEBATE : Expert of the field

TEAM B - Modern Systemic Therapy (Targeted + Maintenance Strategies)

DEBATE : Expert of the field

DISCUSSANT : Expert of the field

12:00 - 12:20 ➤ Sponsored Session

SPEAKER : Expert of the field

12:20 - 12:40 ➤ PARPi in aOC : Beyond BRCA and HRd status

SPEAKER : Dr. Sewanti Limaye

12:40 - 13:00 ➤ Panel Discussion on Endometrium Cancer

MODERATOR : Dr. Boman Dhabhar

13:00 - 13:30 ➤ Robotic Cytoreductive Surgery (CRS) with
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

MODERATOR : Dr. Uddhav Raj

13:30 onwards ➤ Followed by Lunch

HALL B

SESSION 1

- 09:00 - 11:10 > Liquid Biopsy 2026: From Molecular Signal to Clinical Decision — A Pan-Tumor Precision Oncology
SPEAKER : Dr. Prashant Kumar
- 09:00 - 09:15 > Liquid Biopsy 2026: Clinical Integration of ctDNA from Early Detection to Metastatic Disease
SPEAKER : Dr. Kripa Shankar
- 09:15 - 09:30 > ctDNA-Guided Adjuvant Therapy: Are We Ready for MRD-Driven Escalation & De-escalation?
SPEAKER : Dr. Rohit Pai
- 09:30 - 09:50 > Liquid Biopsy vs Tissue Biopsy: Are We Ready to Change the Standard of Care?
Team A - PRO LIQUID BIOPSY (Innovation / Molecular Team)
DEBATE : Expert of the field
TEAM B - PRO TISSUE BIOPSY (Conventional / Gold Standard Team)
DEBATE : Expert of the field
DISCUSSANT : Expert of the field
- 09:50 - 10:15 > Liquid Biopsy in Early Detection & MRD: Clinical Utility vs Clinical Evidence
PANEL : Dr. Jyoti Wadhwa
- 10:15 - 10:25 > Tracking Resistance in Real Time: EGFR, KRAS, HER2 & Beyond Through Plasma Genomics
SPEAKER : Dr. Omshree Setthy
- 10:25 - 10:40 > AI & Multi-Omics in Liquid Biopsy: The Future of Non-Invasive Cancer Surveillance
SPEAKER : Dr. Ram Prasad
- 10:40 - 10:50 > Sponsored Session
SPEAKER : Expert of the field
- 10:50 - 11:20 > A Fireside Chat: Dr Prashant Kumar in Conversation with Dr Sewanti Limaye
“Liquid Biopsy Without Borders: Global Perspective, Unified Vision”
DEBATE : Dr. Prashant Kumar VS Dr. Sewanti Limaye
- 11:20 - 11:30 > **TEA BREAK**

SESSION 2

- 11:30 - 11:45 ➤ Emerging Cellular Therapy in Solid Tumors
SPEAKER : Dr. Kripa Bajaj
- 11:45 - 12:00 ➤ Breaking the Barrier: Overcoming Tumor Microenvironment Resistance in Solid Tumor CAR-T Therapy
SPEAKER : Dr. Dinesh Pendharkar
- 12:00 - 12:30 ➤ Targeted Therapy Beyond the Classics: Are New Biomarkers Ready for Routine Practice?
TEAM A - Emerging Biomarkers should be Integrated into Routine Practice as they improve Outcomes and Expand Treatment Options
DEBATE : Expert of the field
TEAM B - Most New Biomarkers are Promising but Not Yet Ready for Widespread Routine use
DEBATE : Expert of the field
- 12:30 - 12:50 ➤ Is CAR-T Ready for Prime Time in Solid Tumors? Hype, Hope or Imminent Breakthrough?
PANEL : Dr. Vijay Patil
DISCUSSANT : Dr. Suparna Rao | Dr. Sunit Lokwani | Dr. Sumant Gupta
Dr. Shivam Shingla | Dr. Kshitij Joshi

SESSION 3

- MRD 2.0 in Hematologic Malignancies: Flow, NGS & ctDNA in the Era of Cellular Therapy Workshop
CHAIRPERSON : Dr. Tapan Saikia | Dr. A K Ganju
- 12:50 - 13:10 ➤ MRD 2.0 in AML & ALL: Flow Cytometry vs NGS vs Digital PCR — What Should Guide Practice?
TEAM A - Established, Practical Standard (Flow Cytometry)
DEBATE : Expert of the field
TEAM B - Ultra-Sensitive Precision (NGS / Digital PCR)
DEBATE : Expert of the field
DISCUSSANT : Expert of the field
- 13:10 - 13:35 ➤ MRD in Multiple Myeloma: Surrogate Endpoint or True Predictor of Cure?
SPEAKER : Dr. Ankita Jaiswal
- 13:35 - 14:05 ➤ Is MRD Ready to Replace Traditional Response Criteria in Hematologic Malignancies?
MODERATOR : Dr. Mukesh Desai
PANELIST : Expert of the field
- 14:05 - 14:35 ➤ **LUNCH BREAK**

SESSION 4

CHAIRPERSON : Dr. Tapan Saikia | Dr. A K Ganju

14:35 - 14:55 ➤ Molecular Risk Stratification in 2026: Integrating Genomics into Frontline Hematology Practice

SPEAKER : Dr. Salil Vaniawala

14:55 - 15:20 ➤ Monitoring Cellular Therapy: MRD, Immune Reconstitution & Relapse Prediction Post CAR-T & BMT

SPEAKER : Dr. Prashant Tembhare

15:20 - 15:35 ➤ Standardization of Advanced Hematopathology in India: Infrastructure, Accreditation & Quality Control

MODERATOR : Dr. Nikhil Patkar

PANELIST : Dr. Kiran Ghodke | Dr. Kunal Sehgal | Dr. Salil Vaniawala
Dr. Amrit Kaler | Dr. Rashmi Sawant

SESSION 5

Next-Gen CAR-T in Lymphoma & Leukemia

15:35 - 15:50 ➤ Second-Generation vs Next-Gen CAR-T: Dual Targeting, Armored CARs & Allogeneic Platforms

SPEAKER : Dr. Gaurav Narula

15:50 - 16:20 ➤ Sequencing CAR-T, Bispecific Antibodies & Transplant in Lymphoma and ALL:
What is the Optimal Strategy in 2026?

SPEAKER : Expert of the field

16:20 - 16:50 ➤ CAR-T Cell Therapy in Hematologic Malignancies: Transforming Outcomes or Redefining Challenges?

MODERATOR : Dr. Vipul Sheth

PANELIST : Dr. Sameer Tulpule | Dr. Lingaraj Nayak | Dr. Shrinath Kshirsagar
Dr. Balkrishna Padate

16:50 - 17:10 ➤ TEA BREAK

SESSION 6

Quadruplets, Bispecifics & CAR-T Updates

- 17:10 - 17:30 > Frontline Quadruplet Therapy in Transplant-Eligible & Ineligible Myeloma: Is MRD the New Endpoint?
SPEAKER : Expert of the field
- 17:30 - 17:50 > Bispecific Antibodies and CAR-T in Earlier Lines: Are We Moving Toward a Functional Cure in Myeloma?
SPEAKER : Expert of the field
- 17:50 - 18:20 > Are We Overtreating Multiple Myeloma in the Era of Novel Immunotherapies?
TEAM A - Current use of Quadruplets, Bispecifics, and CAR-T is leading to overtreatment in many Patients without Clear Survival Benefit.
DEBATE : Expert of the field
TEAM B - Intensified therapy with Novel Immunotherapies is improving Outcomes and should be used early to Maximize Survival
DEBATE : Expert of the field
DISCUSSANT : Expert of the field
- 18:20 - 18:55 > Sequencing Quadruplets, Bispecifics & CAR-T: What Is the Optimal Treatment Algorithm in 2026?
MODERATOR : Dr. Balkrishna Padate **PANELIST : Expert of the field**
- Molecular Stratification & Targeted Therapy 2025
- 18:55 - 19:15 > Precision Risk Stratification in AML 2025: Integrating Genomics, MRD & ELN Updates into Clinical Practice
SPEAKER : Dr. Shilpa Gupta
- 19:15 - 19:35 > Targeted Therapy Beyond 7+3: FLT3, IDH, TP53 & Venetoclax-Based Combinations in the Modern AML Era
SPEAKER : Expert of the field
- 19:35 - 20:00 > Is Intensive Chemotherapy Still the Backbone in AML? Defining the Optimal Strategy in a Targeted Therapy Era
MODERATOR : Dr. Sameer Tulpule
PANELIST : Dr. Shivam Shingla | Dr. Adwaita Gore | Dr. Abhay Bhawe
Dr. Rajesh Patil | Dr. Shilpa Gupta
- ALL & CLL - Novel Agents & Outcomes
- 20:00 - 20:20 > Chemotherapy-Free ALL: Bispecific Antibodies, CAR-T & MRD-Directed Therapy in 2026
SPEAKER : Dr. Shrinath Kshirsagar
- 20:20 - 20:50 > From Continuous Therapy to Functional Cure: Are We Redefining Long-Term Outcomes in ALL & CLL?
MODERATOR : Expert of the field
- 20:50 - 21:10 > Expanding Horizons of CINV Prevention: NEPA in the Era of ADCs (Glenmark)
SPEAKER : Dr. Mubarkunnisa Tonse

SESSION 7

Chairperson Dr. Purna Kurkure

- 09:00 - 09:20 ➤ High-Risk Neuroblastoma in 2026: Immunotherapy, GD2 Targeting & MRD-Guided Consolidation Strategies
SPEAKER : Dr. Parth Ganatra
- 09:20 - 09:4 ➤ Precision & Organ Preservation in Pediatric Solid Tumors: Evolving Strategies in Wilms Tumor and Sarcomas
SPEAKER : Dr. Shweta Bansal
- 09:40 - 10:10 ➤ Challenging Case Discussions
CASE PRESENTER STUDENT 1 Wadia Hospital
CASE PRESENTER STUDENT 2 Nair Hospital
CASE PRESENTER STUDENT 3 H. N. Reliance Hospital
CASE PRESENTER STUDENT 4 BMT Center Borivali
DISCUSSANT : Expert of the field
- 10:10 - 10:30 ➤ Advances in Pediatric ALL & AML
SPEAKER : Expert of the field
- 10:30 - 11:00 ➤ Transforming Pediatric ALL: Integrating Targeted Therapy & Immunotherapy into Frontline Practice
SPEAKER : Dr. Santanu Sen
- 11:00 - 11:30 ➤ Breakfast / Tea Break

SESSION 8

Chairperson Dr. Mukesh Desai

- 11:30 - 11:50 ➤ Allogeneic Transplant & GVHD 2025
SPEAKER : Sponsored Expert
- 11:50 - 12:10 ➤ Post-Transplant MRD & Maintenance
SPEAKER : Dr. Reetu Jain
- 12:10 - 12:30 ➤ Ransplant vs CAR-T Sequencing: Which Should Come First in High-Risk Hematologic Malignancies?
TEAM A - Allo Transplant Remains The Backbone of Cure
TEAM B - Cellular Therapy is Redefining Cure Pathways
DISCUSSANT : Expert of the field
DEBATE : Expert of the field
DEBATE : Expert of the field
- 12:30 - 13:00 ➤ Transplant vs CAR-T Sequencing
MODERATOR : Dr. Sameer Tulpule
PANELIST : Dr. Ganapathi Bhat | Dr. Varun Bafna | Dr. Balkrishna Padate
Dr. Shrinath Kshirsagar | Dr. Chintan Vyas
- 13:00 - 13:30 ➤ Closing Remarks Followed by Lunch



The Best Healthcare Services

Plan My treatment offers comprehensive services for national and international patients seeking treatment in India. We facilitate treatments across specialties, handle travel arrangements, assist with visas, provide language interpretation, offer cost estimation and financial planning, and ensure personalized care. Our aim is to provide top-quality healthcare and a seamless experience for our valued indian and international patients.



**Video Consultation &
Free Estimation**



**Visa
Assistance**



**Airport Pick up & Drop
For patient and attendant**



**Hand
Holding**



**Quality Medical
Treatment**



+91 89767 42348



105, Civic Centre, 1st Floor M.M.G.S. Marg, Opp. Sunshine Plaza,
Dadar(E), Mumbai - 400 014



care@planmytreatment.com



www.planmytreatment.com

Thank you

Thank you!
TO OUR SPONSORS

